Ziyad Al-Aly, MD
@zalaly
Physician-Scientist | TIME100 Health https://time.com/6966812/ziyad-al-aly/ Profile: http://outlook.wustl.edu/real-world-ref…
My full testimony before the U.S. Senate Committee on Health, Education, Labor and Pensions Video here thanks to @luckytran 👇
"The burden of disease and disability from Long COVID is on par with the burden of cancer and heart disease. The best way to prevent Long COVID is to prevent COVID in the first place. There is no Long COVID without COVID." Brilliant testimony by @zalaly! #HELPLongCovid
This thread is a great explainer of our paper on the benefits and risks GLP-1 drugs nature.com/articles/s4159… Thanks @fperrywilson for this informative thread.
Every week, I see a new study talking about this or that effect of GLP-1 receptor agonists like #ozempic. FINALLY, we have a study evaluating all the outcomes (good and bad) in one dataset. There are some... surprises. 🧵
New Long Covid policy paper from Norway outlines knowledge gaps and lessons learnt for developing preparedness for future pandemics. Section 5 (pictured below) outlines their recommendations. Led by Sara Illman, PhD and colleagues. nordforsk.org/2025/knowledge…
🚨 ICYMI: Our latest study shows that the popular GLP-1 weight loss drugs (e.g. Ozempic) have broad health benefits — reducing risks of 42 health conditions. They are not without risks — increasing risks of of 19 health conditions. nature.com/articles/s4159…
🚨 New from my team: In a study of over 2 million people, we comprehensively mapped the benefits and risks of GLP-1 (weight loss drugs) across 175 health conditions. 📄 Free access to the full study: rdcu.be/d6VYU 🧵 Explore the key findings: x.com/zalaly/status/…
1. What are the benefits and risks of GLP1? Our new study in @naturemedicine comprehensively maps all the benefits and risks of GLP-1 receptor agonists (GLP-1) (Ozempic, Wegovy, Mounjaro, Zepbound). By @Biostayan, Taeyoung Choi and me 🧵 nature.com/articles/s4159…
1. What are the benefits and risks of GLP1? Our new study in @naturemedicine comprehensively maps all the benefits and risks of GLP-1 receptor agonists (GLP-1) (Ozempic, Wegovy, Mounjaro, Zepbound). By @Biostayan, Taeyoung Choi and me 🧵 nature.com/articles/s4159…
Honored to speak at @Harvard’s Radcliffe Institute workshop on #LongCOVID. I am energized by our 2 days of brainstorming about the road ahead. The challenges are real, but I’m leaving hopeful. Millions living with Long Covid are counting on our progress—we must keep keep pushing…
GLP-1 drugs are revolutionizing the way we think about obesity. It is a chronic disease (like high blood pressure), and might actually be a form of food addiction. One reason these drugs are so effective in treating obesity could be that they address the underlying addiction. We…
Alzheimer, addictions, dépression… les effets bénéfiques de l’Ozempic et des médicaments apparentés My Ozempic piece has been translated into French; thanks the amazing team at Conversation in Paris. @FR_Conversation theconversation.com/alzheimer-addi…
I talked to Dani Blum from @nytimes about the potential role of GLP-1 drugs on Alzheimer’s disease. They seem promising, but more data is needed for sure. nytimes.com/2025/01/31/wel…
Thanks to @DKThomp for hosting me on his podcast. We talked about the GLP-1 and more. Details in this post below.
New ep: Are GLP-1s "the greatest medical breakthrough of the 21st century"? A new study of 2m Veterans Affairs patients with diabetes found GLP1 use was associated with a reduced risk of: - substance use disorders - psychotic disorders - Alzheimer's and dementia - clotting and…
🚨 I dive into the benefits and risks of Ozempic and similar weight loss drugs in this article for @ConversationUS 💊 These drugs may lower the risk of 42 health conditions but aren’t without risks theconversation.com/ozempic-and-si… Free PDF of original article rdcu.be/d6VYU
Let me address this. We wrote the grant to do this project in 2018. It was funded in 2020. We deliberately delayed this to devote time and effort to addressing Covid and Long Covid. My team and I remain committed to working on LC, but we cannot default on our other commitments.
I must admit, I'm disappointed the most trusted voice in Long COVID research has dedicated time to non-COVID study. There must be enough researchers around who can study GLP-1. Meanwhile, LC sufferers need solutions and most people are ignoring the risks of COVID reinfections.